Open AccessMetastatic urothelial carcinoma harboring ERBB2/3 mutations dramatically respond to chemotherapy plus anti-PD-1 antibody: A case report
Author(s) -
Feifei Yan,
Qi Jiang,
Bin Ru,
Xiao-Jie Fei,
Jian Ruan,
XiaoChen Zhang
Publication year - 2022
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v10.i8.2497
Subject(s) - medicine , metastatic urothelial carcinoma , oncology , immunotherapy , biomarker , chemotherapy , paclitaxel , carcinoma , cancer , urothelial carcinoma , afatinib , lung cancer , bladder cancer , cancer research , epidermal growth factor receptor , gefitinib , biochemistry , chemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom